Company news
BioAge Labs, Inc. news in 2025
BioAge Labs, Inc.'s news releases, calls and decks from 2025, newest first.
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
December 4, 2025
BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference
November 25, 2025
BioAge Labs to Present at Jefferies Global Healthcare Conference in London
November 7, 2025
BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates
November 6, 2025
HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor
September 14, 2025
BioAge Labs to Present at Upcoming Investor Conferences
August 20, 2025
BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
August 15, 2025
BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates
August 6, 2025
BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions
June 21, 2025
BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank
June 17, 2025
BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates
June 3, 2025
BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic
May 29, 2025
BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates
May 6, 2025
BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024
March 20, 2025
BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference
February 20, 2025
BioAge Labs Announces Company Updates on APJ, NLRP3, and Platform Programs
January 27, 2025